Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

Open access

Abstract

Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents to malignant cells. In the past three years, the number of ADCs approved by the Food and Drug Administration (FDA) has tripled. Although several ADCs have demonstrated sufficient efficacy and safety to warrant FDA approval, the clinical use of all ADCs leads to substantial toxicity in treated patients, and many ADCs have failed during clinical development due to their unacceptable toxicity profiles. Analysis of the clinical data has demonstrated that dose-limiting toxicities (DLTs) are often shared by different ADCs that deliver the same cytotoxic payload, independent of the antigen that is targeted and/or the type of cancer that is treated. DLTs are commonly associated with cells and tissues that do not express the targeted antigen (i.e., off-target toxicity), and often limit ADC dosage to levels below those required for optimal anti-cancer effects. In this manuscript, we review the fundamental mechanisms contributing to ADC toxicity, we summarize common ADC treatment-related adverse events, and we discuss several approaches to mitigating ADC toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15030713

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanisms of ADC toxicity. Uptake of intact ADCs into normal cells may occur through non-specific endocytosis, or through internalization upon binding to the target antigen or to Fc/C-type lectin receptors. Payloads released from ADC deconjugation or other targeted/non-targeted apoptotic cells in the extracellular fluid may also enter normal cells via passive diffusion for membrane-permeable payloads or via non-specific endocytosis for membrane-impermeable linker-payload adducts. Created with BioRender.com.
Figure 1 Mechanisms of ADC toxicity. Uptake of intact ADCs into normal cells may occur through non-specific endocytosis, or through internalization upon binding to the target antigen or to Fc/C-type lectin receptors. Payloads released from ADC deconjugation or other targeted/non-targeted apoptotic cells in the extracellular fluid may also enter normal cells via passive diffusion for membrane-permeable payloads or via non-specific endocytosis for membrane-impermeable linker-payload adducts. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 224 references

Research works printed but not linked: 5

  1. GlaxoSmithKline (2023, January 17). GSK Provides an Update on Blenrep (Belantamab Mafodotin-Blmf) US Marketing Authorisation. Available online: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/.
  2. Actor, J.K. (2012). Elsevier’s Integrated Review Immunology and Microbiology, W.B. Saunders. [2nd ed.].
  3. Herrera, 2017, A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL), Blood, 130, 4129
  4. Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI
  5. Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI

Cited by

See all 441

Metadata

Authors
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P.
Affiliations
University at Buffalo, State University of New York (US)
Corresponding author
Balthasar, Joseph P.
Venue
Cancers
Publisher
MDPI AG
Published
2023-01-24
Volume
15
Issue
3
Pages
713
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4317932204
Cited by
441
References
224
Citations by year
2026: 150 · 2025: 172 · 2024: 99 · 2023: 20
FWCI
18.58
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (CA246785, CA256928)
  • University at Buffalo Center for Protein Therapeutics (CA246785, CA256928)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
antibody-drug conjugates, off-target toxicity, dose-limiting toxicity, treatment-related adverse events, toxicity mechanisms, tolerability, cytotoxic payloads, monoclonal antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. https://app.cochat.ai/papers/10.3390/cancers15030713
The paper
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers. https://doi.org/10.3390/cancers15030713

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.